Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

Inclusion Criteria:

* Age ≥ 18 years
* Metastatic colorectal cancer
* Progression on or following standard therapy, or no standard therapy (phase Ib). Progression on or following at least 2-prior fluoropyrimidine-containing chemotherapy regimens (phase II)
* Written documentation of mutant or wild-type RAS
* Life expectancy ≥ 3 months
* ECOG performance status ≤ 2

Exclusion Criteria:

Phase II arms 1 and 4 only: previous treatment with cetuximab, panitumumab, and/or other EGFR inhibitors

* Previous treatment with MEK-inhibitors
* History of severe infusion reactions to monoclonal antibodies.
* Symptomatic or untreated leptomeningeal disease
* Symptomatic brain metastasis
* Current evidence of retinal disease; history of CSR, RVO or ophthalmopathy as assessed by ophthalmologic examination at baseline that would be considered a risk factor for CSR/RVO and history of keratitis.
* Acute or chronic pancreatitis
* Clinically significant cardiac disease
* Not adequate hematologic, renal and hepatic function